Oruka Therapeutics (NASDAQ:ORKA) Receives Outperform Rating from Wedbush

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating reissued by equities researchers at Wedbush in a research note issued to investors on Thursday, Benzinga reports. They currently have a $165.00 target price on the stock. Wedbush’s price target suggests a potential upside of 90.38% from the stock’s previous close.

A number of other research analysts have also commented on ORKA. UBS Group upped their target price on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Piper Sandler reiterated an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Finally, Mizuho set a $120.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $128.91.

Oruka Therapeutics Price Performance

Shares of Oruka Therapeutics stock traded down $3.26 during midday trading on Thursday, hitting $86.67. The company had a trading volume of 232,094 shares, compared to its average volume of 1,097,900. The business’s 50 day simple moving average is $96.79 and its two-hundred day simple moving average is $75.32. The stock has a market cap of $5.74 billion, a PE ratio of -42.67 and a beta of -0.34. Oruka Therapeutics has a 1-year low of $14.89 and a 1-year high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, sell-side analysts expect that Oruka Therapeutics will post -2.42 EPS for the current fiscal year.

Insider Activity

In other news, CEO Lawrence Klein sold 75,000 shares of the company’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total value of $6,887,250.00. Following the completion of the sale, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at $84,996,011.40. This represents a 7.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00. Following the completion of the sale, the senior vice president directly owned 15,312 shares of the company’s stock, valued at approximately $1,633,177.92. This trade represents a 39.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 122,950 shares of company stock valued at $11,528,806. 23.49% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Oruka Therapeutics

Several institutional investors have recently modified their holdings of ORKA. BlackRock Inc. bought a new position in shares of Oruka Therapeutics during the 2nd quarter valued at about $474,916,000. Jupiter Topco LLC bought a new stake in Oruka Therapeutics during the second quarter worth about $130,968,000. Bank of America Corp DE bought a new stake in Oruka Therapeutics during the second quarter worth about $33,578,000. Braidwell LP bought a new stake in Oruka Therapeutics during the second quarter worth about $26,473,000. Finally, Atika Capital Management LLC bought a new stake in Oruka Therapeutics during the first quarter worth about $11,277,000. Institutional investors own 56.44% of the company’s stock.

More Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and set a $165 price target, implying substantial potential upside from the referenced $89.93 level. Tickerreport analyst rating article
• Positive Sentiment: HC Wainwright also reaffirmed its “buy” rating and assigned a $120 price target, indicating continued analyst confidence in Oruka’s pipeline and valuation. StreetInsider analyst rating article
• Positive Sentiment: Oruka reported encouraging Week 28 results from the Phase 2a EVERLAST-A trial of ORKA-001 in moderate-to-severe plaque psoriasis. PASI 100 responses increased to 71.4% and PASI 90 responses to 87.3%, despite no additional dosing after Week 4, suggesting durable and deepening treatment effects. Oruka EVERLAST-A Week 28 results
• Positive Sentiment: Placebo-crossover patients achieved PASI 90 and PASI 100 response rates comparable to patients initially treated with ORKA-001, while the therapy continued to show a favorable safety and tolerability profile. Additional EVERLAST-A data are expected in December 2026, with EVERLAST-B results expected in the fourth quarter. MarketScreener trial results
• Negative Sentiment: Oruka shares fell after the Week 28 release despite improving psoriasis responses. The reaction suggests investors may have already anticipated strong data, or may be focused on the need for additional validation from upcoming 52-week and follow-on trial results. Yahoo Finance market reaction

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.